HomeEXECUTIVESNoninvasix Appoints David J. Giarracco as CEO

Noninvasix Appoints David J. Giarracco as CEO

Noninvasix reported today that David J. Giarracco has been appointed the new CEO of the company. A veteran medical device executive with relevant critical care market experience, Giarracco will advance the commercialization of the only non-invasive patient monitoring device designed for earlier detection of life-threatening sepsis so it can be treated to improve patient outcomes.

Dave is the right leader at the right time for Noninvasix,” said Tom Luby, Ph.D., Director of Texas Medical Center Innovation Venture Fund. “He has a deep understanding of launching new platform technologies that make a critical difference in patient safety and clinical outcomes while reducing overall healthcare costs.”

Giarracco has extensive experience in the launch and global commercialization of novel patient-monitoring technologies in both hospital and home care settings. In leadership roles at Medtronic and Covidien, he successfully scaled organizations to exceed business plans by strategically developing markets, addressing commercial structure, and creating clinically focused, solution-selling organizations. Giarracco combines this expertise with start-up experience as chief operations officer at SeaStar Medical and as a lead investor and board member at early-stage healthcare technology companies.

“Dave will play an essential role in helping refine our strategy and drive product development activity to realize our mission of better detecting and monitoring sepsis,” said Dr. Donald Prough, Rebecca Terry White Distinguished Professor and Chairman of the Department of Anesthesia at the University of Texas Medical Branch. “As a Noninvasix founder and practicing anesthesiologist, I am excited about our future and the opportunity to make a significant impact on this major healthcare challenge.”

“Prevention and control strategies for sepsis infections are urgently needed,” said Giarracco. “We need new, non-invasive approaches for early diagnosis to reduce complications and save lives. Noninvasix technology promises to make a major difference in patient care, reduce healthcare costs and have wider applications beyond sepsis.”

Giarracco received his Bachelor of Science in Biomedical Engineering from The Johns Hopkins University and his Master of Arts in Biomedical Engineering from The Johns Hopkins School of Medicine. He brings more than 25 years of medical technology experience as an engineer, commercial leader, and early-stage investor in innovative, category-defining technologies.


Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.


“We’re delighted to welcome Gerald and Hannah to the PrecisionLife team at a time when our deep disease insights and patient stratification biomarkers are finding important new markets and bringing precision approaches to the early, more accurate diagnosis and care of patients with complex chronic diseases,” said Dr Steve Gardner, PrecisionLife CEO.
Broken String Biosciences reports Gavin Burns will be responsible for building and optimizing the companys teams, processes, and systems.
“We are pleased to strengthen our Clinical Advisory Board and to welcome our new members,” commented Pierre Leurent, President, Aptar Digital Health. “Their broad medical expertise will allow us to have a deeper knowledge and expand our global vision of the clinical practice for multiple types of cancer.”
Dr Ronald Silverman will be responsible for leading the company's Medical Affairs organization, which includes end-to-end medical affairs across BD's business units, regions and central team. In this role, he will use medical insights and expertise to advance BD's pipeline of clinically relevant, innovative solutions that align with evolving patient needs, while also contributing to the safety and compliance of BD's in-market portfolio of products.
"Bill Hoffman is a widely respected and accomplished leader in the MedTech industry. The company is certain to benefit from his experience and insights as it looks to achieve its upcoming clinical milestones and future commercial goals," said Dr. David Israeli, CEO of Magenta Medical.

By using this website you agree to accept Medical Device News Magazine Privacy Policy